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Dipeptidyl peptidase-4 inhibitors, 
pancreatic cancer and acute 
pancreatitis: A meta-analysis with 
trial sequential analysis
Lana C. Pinto, Dimitris V. Rados, Sabrina S. Barkan, Cristiane B. Leitão & Jorge L. Gross
The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and 
acute pancreatitis. Recent meta-analyses have reported conflicting findings. Therefore, we performed a 
meta-analysis to assess the risk of both pancreatic cancer and acute pancreatitis associated with the use 
of DPP-4 inhibitors. We also used trial sequential analysis to evaluate whether the number of patients 
included was enough to reach conclusions. We included randomised controlled trials lasting 24 weeks 
or more that compared DPP-4 inhibitors with placebo or other antihyperglycaemic agents. A total of 
59,404 patients were included. There was no relationship between the use of DPP-4 inhibitors and 
pancreatic cancer (Peto odds ratio 0.65; 95% CI 0.35–1.21), and the optimal sample size was reached 
to determine a number needed to harm (NNH) of 1000 patients. DPP-4 inhibitors were associated 
with increased risk for acute pancreatitis (Peto odds ratio 1.72; 95% CI 1.18–2.53), with an NNH of 
1066 patients, but the optimal sample size for this outcome was not reached. In conclusion, there is no 
association between DPP-4 inhibitors and pancreatic cancer, and a small risk for acute pancreatitis was 
observed with DPP-4 inhibitor use, although the latter finding is not definitive.
Dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins, are incretin-mimetic oral antihyperglycaemic agents 
whose clinical use has steadily increased over the past ten years1. These medications are not associated with severe 
hypoglycaemia and have a neutral effect on weight. However, there are concerns that the use of DPP-4 inhibitors 
may be associated with increased risk for pancreatic cancer and acute pancreatitis2,3.
An early study analysed the FDA reports of pancreatic cancer and concluded that there was a 2.7-fold increase 
in the risk for pancreatic cancer with DPP-4 inhibitor use2. Another study suggested that DPP-4 inhibitor use was 
associated with the occurrence of α-cell hyperplasia, that is, increased proliferation and dysplasia, with potential 
evolution into neuroendocrine tumours4. Later, a pooled analysis of clinical trials with sitagliptin suggested no 
association between use of this medication and pancreatic cancer5. The lack of association between DPP-4 inhib-
itor use and pancreatic cancer was evaluated in a pooled analysis including only two large randomised trials, and 
no association was found6. Recently, three meta-analyses assessed the risk for acute pancreatitis among patients 
taking gliptins. Li et al. analysed the results of 60 randomised and non-randomised trials and found no increased 
risk of pancreatitis in patients treated with gliptins compared with controls7. Despite this reassuring finding, the 
inclusion of observational studies might have influenced the results owing to selection bias. Conversely, two other 
meta-analyses found contradictory results when analysing the results of three large studies assessing the cardi-
ovascular risk of sitagliptin, saxagliptin and alogliptin1,3. In these studies, the use of DPP-4 inhibitors increased 
the risk of pancreatitis. Importantly, the potential cases of acute pancreatitis were adjudicated in these three trials.
Considering the potential association between DPP-4 inhibitor use and both pancreatic cancer and acute pan-
creatitis, we performed a meta-analysis including all randomised trials with DPP-4 inhibitor use lasting at least 
24 weeks, in order to analyse whether there is an increased risk of pancreatic cancer and/or acute pancreatitis. We 
also applied trial sequential analysis (TSA) to assess whether the number of patients randomised in these trials 
was sufficient to reach definitive conclusions.
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Methods
Protocol and registration. This systematic review and meta-analysis follows the recommendations of the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) protocol8 and was registered in 
the International Prospective Register of Systematic Reviews (PROSPERO) under the number CRD42016953346.
Patient Involvement. No patients were directly involved in the study.
Information source and search strategy. We performed a systematic literature search for all randomised 
clinical trials (RCTs) that compared DPP-4 inhibitor use with either placebo or other antihyperglycaemic medi-
cations. We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and 
ClinicalTrials.gov from database inception to May 2016. We also searched abstracts from the most recent meet-
ings of the American Diabetes Association and the European Association for the Study of Diabetes. The search 
strategy used the Medical Subject Headings (MeSH) terms “sitagliptin” OR “saxagliptin” OR “linagliptin” OR 
“alogliptin” OR “vildagliptin” AND “diabetes mellitus, type 2” AND a validated filter to identify RCTs9. All eligible 
trials were considered for review, regardless of language. A manual search of the reference lists of key articles was 
also performed.
Eligibility criteria. The inclusion criteria were: (1) RCTs, (2) DPP-4 inhibitor use versus any standard of 
comparison, (3) treatment for at least 24 weeks, (4) definition of events of acute pancreatitis and/or pancre-
atic cancer, (5) inclusion of patients ≥18 y old, and (6) diagnosis of type 2 diabetes according to the American 
Diabetes Association criteria10.
Study selection and data collection. Two independent investigators (L.C.P. and S.S.B.) selected studies 
on the basis of titles and abstracts. Studies satisfying the inclusion criteria and those with abstracts that lacked 
crucial information to decide upon their exclusion were retrieved for full-text evaluation. Both investigators 
also analysed the selected trials and extracted data; disagreements were resolved by a third reviewer (D.V.R.). 
The following information was extracted: first author’s name, year of publication, sample size and dropouts, age 
distribution, gender distribution, trial duration, treatment in use prior to randomisation, acute pancreatitis and 
pancreatic cancer events.
Risk of bias in individual studies and the quality of meta-analysis. The quality of studies was 
assessed according to the Cochrane Collaboration tool for risk of bias, including the following six domains: 
random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, 
and other biases such as adjudication of events11,12. In adjudicated trails, the diagnosis was confirmed by the 
following criteria: symptoms of abdominal pain or vomiting and evidence of pancreatic inflammation (e.g., ele-
vated pancreatic enzymes, amylase or lipase >3× the normal upper limit; in patients with chronic pancreatitis, 
enzyme elevations >2× the normal upper limit) or evidence of acute pancreatitis documented by abdominal 
computerised tomography, magnetic resonance imaging or ultrasound showing focal, diffuse and inhomoge-
neous gland enlargement. The quality of each outcome (pancreatic cancer and acute pancreatitis) was evaluated 
by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach13. Each 
meta-analysis was rated as high, moderate, low or very low quality.
Synthesis of results. We compared the events of interest between patients randomised to the use of DPP-4 
inhibitors and patients randomised to the control treatment (placebo or other antihyperglycaemic medications). 
The outcomes of interest were pancreatic cancer and acute pancreatitis.
Data were summarised with direct meta-analysis to compare DPP-4 inhibitors with placebo and other anti-
hyperglycaemic agents. We used the Peto odds ratio and the Mantel-Haenszel test for analysis. We used the Peto 
odds ratio in the primary analyses as it is more conservative (can identify smaller associations) and is superior 
when dealing with rare events. Heterogeneity was assessed by Cochran’s Q test (a p-value of 0.1 was considered 
statistically significant) and the I2 test (values greater than 50% were considered to indicate elevated statisti-
cal heterogeneity). For studies with no events in either arm, continuity correction was performed to include 
these data in TSA analyses. To assess whether the length of the trials was related to the outcome, we performed 
meta-regression, using study duration as a covariate.
Furthermore, to address whether current information is sufficient for firm conclusions, we performed TSA of 
the identified studies. This analysis is analogous to sample size estimation or interim analysis of a single study14,15 
and is associated with a cumulative meta-analysis represented by the Z-curve. Therefore, we calculated the sam-
ple size required to detect or reject a minimal relevant difference between DPP-4 inhibitors and the control1,4. 
We defined this minimal relevant difference as an absolute difference of 0.1% in the incidence of both outcomes 
(pancreatic cancer and acute pancreatitis) between groups on the basis of previous trial results1. We conducted 
the TSA with an overall 5% risk of type I error and 20% risk of type II error (power of 80%).
We evaluated publication bias with visual inspection of funnel plots and with Begg’s and Egger’s tests. If 
small-study bias was identified, we applied the trim-and-fill method to explore the effect of missing studies on 
the outcomes.
The analyses were performed using the programs RevMan version 5.3 (Cochrane Collaboration, Copenhagen, 
Denmark) and STATA 12.0 (Stata Inc., College Station, Texas, USA). The TSA was performed with TSA software 
(Centre for Clinical Intervention Research Department, Copenhagen, Denmark).
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Results
Our search retrieved 763 articles. After we scanned through the titles and abstracts and removed all duplicates, 
186 articles remained for full-text evaluation. Ultimately, 38 trials were included in the analysis (Fig. 1 – Study 
Flowchart).
The selected studies were published between 2009 and 2015. The mean trial duration was 63.5 weeks (range, 
24–260). The analysis included 59,404 patients; 39,970 (62.1%) were men, and the mean age was 57.39 ± 5.12 
years. The main characteristics of the included trials are presented in Table 1. Results regarding the individual 
quality of the included trials are presented in Supplemental Material.
The analysis of the funnel plots and Begg’s and Egger’s tests suggested no publication bias for either outcome 
(pancreatic cancer or acute pancreatitis).
DPP-4 inhibitors and pancreatic cancer. There were 16 events of pancreatic cancer in the DPP-4 
inhibitor group and 24 events in the control group. DPP-4 inhibitors were not associated with increased risk 
for pancreatic cancer in the direct meta-analysis (Peto odds ratio 0.65; 95% CI 0.35–1.21) (Fig. 2A – Forest 
plot for association between DPP-4 inhibitors and pancreatic cancer). Similar results were observed with the 
Mantel-Haenszel test (0.65; 95% CI 0.35–1.19). When we performed TSA, DPP-4 inhibitors were still not asso-
ciated with pancreatic cancer (Peto odds ratio 0.66; 95% CI 0.36–1.19), and the number of randomised patients 
for this outcome surpassed the futility boundary (Fig. 2B – TSA for pancreatic cancer). Meta-regression did not 
show an interference of study duration with the outcome (p = 0.867; 8 studies included) (Supplemental Material).
DPP-4 inhibitors and acute pancreatitis. There were 64 events of acute pancreatitis in the DPP-4 inhib-
itor group and 39 events in the control group. DPP-4 inhibitors were associated with an increased risk of acute 
pancreatitis in direct meta-analysis (Peto odds ratio 1.72; 95% CI 1.18–2.53; Supplemental Material) and with an 
absolute risk difference of 0.1% (representing a number needed to harm (NNH) of 1066). Mantel-Haenszel anal-
ysis showed comparable results (1.52; 95% CI 1.05–2.18). As we aimed to be conservative, TSA was performed 
to assess whether there was enough information to reach a definite conclusion regarding the association between 
DPP-4 inhibitors and acute pancreatitis. For this outcome, the number of patients evaluated (n = 59,404) did not 
reach the optimal sample size (n = 140,665), and the boundaries of benefit, harm and futility were not crossed 
(Peto odds ratio 1.34; 95% CI 1.00–1.79). In meta-regression, no interference of study duration with acute pan-
creatitis was seen (p = 0.252; 25 studies included).
Discussion
The results of the present review indicate that the use of DPP-4 inhibitors is not associated with increased risk 
for pancreatic cancer. Furthermore, the TSA meta-analysis confirmed that the number of patients available was 
enough to reach this conclusion. There seemed to be an association between the use of DPP-4 inhibitors and 
acute pancreatitis, although the number of randomised patients was not sufficient for a firm conclusion and the 
estimated risk of acute pancreatitis is small (one patient in 1066 patients treated with DPP-4 inhibitors).
Concern regarding the association between DPP-4 inhibitor use and pancreatic cancer was raised after a 
review of cases reported by the FDA2. Other studies have suggested an association between DPP-4 inhibitor use 
and pancreatic cancer4,5, but there is still an ongoing debate on this topic. Additionally, several observational 
studies have explored the association between DPP-4 inhibitors and pancreatitis16,17. However, owing to study 
design characteristics, the results may be affected by selection and confounding biases. As there are a great num-
ber of randomised trials evaluating these medications, a systematic review and meta-analysis of these studies is 
recommended to properly address this clinical question.
Figure 1. Study flowchart.
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Before this review, three other meta-analyses evaluated the association between clinical use of DPP-4 inhib-
itors and acute pancreatitis. The first one7 did not find an association between use of DPP-4 inhibitors and acute 
pancreatitis; however, this review included not only randomised trials but also prospective and retrospective 
observational cohort studies. Most importantly, the events were not adjudicated. The other two1,3 found an 
increased risk of acute pancreatitis in patients treated with DPP-4 inhibitors; however, they included only three 
large cardiovascular randomised trials, namely, EXAMINE, SAVOR-TIMI 53 and TECOS18–20. In these trials, a 
specialised committee adjudicated the diagnosis of acute pancreatitis. None of these reviews performed TSA to 
evaluate whether the results were definitive, and, more importantly, none of them evaluated the risk of pancreatic 
cancer associated with use of DPP-4 inhibitors.
Our study adds new information regarding this point. It included all randomised trials with DPP-4 inhibitor 
use that lasted for at least 24 weeks and, through TSA meta-analysis, evaluated whether the number of cases 
was sufficient to support the conclusions. There was a small risk of acute pancreatitis, such that it would be 
necessary to treat 1066 patients to have one case of acute pancreatitis, but the number of patients included in 
the meta-analysis was not sufficient to support this conclusion. Notably, owing to the large number of diabetic 
patients using DPP-4 inhibitors worldwide, a great number of cases of acute pancreatitis might be prevented by 
taking into account pre-existing risk factors for acute pancreatitis, such as gallstones and hypertriglyceridaemia, 
when considering whether to prescribe this type of medication.
Author Year n Follow-up (weeks) Men (%) Mean age (y) Background treatment
Ahren 2014 1012 104 47.6 54.4 Metformin
Araki 2013 561 26 70.4 60.0 Naïve or OADs
Arechevaleta 2011 1035 30 54.4 56.3 Metformin
Arjona-Ferreira 2013 426 54 59.8 64.2 Diet, Exercise or OAD
Bajaj 2014 272 24 48.5 53.8 Metformin + Pioglitazone
Barnett 2012 455 52 41.3 58.0 Insulin or Insulin + Metformin
Bergenstal 2010 514 26 51.7 52.5 Metformin
TECOS 2015 14671 260 70.7 66.0 Metformin, Pioglitazone, Sulfonylurea or Insulin
DeFronzo 2015 674 24 53.7 56.2 Metformin
DeFronzo 2012 743 26 46.4 54.1 Metformin
Del Prato 2014 2639 104 49.7 55.4 Metformin
Fredrich 2012 366 24 45.9 54.9 Naïve
Gallwitz 2012 1552 104 60.2 59.8 Metformin
Henry 2014 1615 54 56.5 NR Diet, Exercise, Metformin or Sulfonylurea
Hollander 2009 565 24 49.6 54.0 Thiazolidinedione
Inagaki 2013 574 52 69.9 60.9 OADs
Jadzinsky 2009 1309 24 49.2 52.0 Naïve
SAVOR-TIMI 53 2013 16492 140 66.9 65.0 Non-incretin therapies
Leiter 2014 507 52 53.7 63.3 OADs
Lewin 2015 667 24 53.8 54.6 Naïve
Mintz 2014 858 104 51.7 57.6 Metformin
Nauck 2007 1172 52 59.2 56.7 Metformin
Nauck 2014 1098 104 46.5 54.1 Metformin
Nowicki 2011 170 52 42.9 66.5 OADs or Insulin
Olansky 2011 1250 44 56.8 49.7 Diet + Exercise
Pfutzner 2011 1306 76 49.2 52.0 Naïve
Pratley 2012 665 52 52.9 55.3 Metformin
Rosenstock 2009 401 24 50.9 53.5 Naïve
Rosenstock 2009 390 26 41.3 NR Insulin
Rosenstock 2010 655 26 48.9 52.6 Naïve
Schernthaner 2013 756 52 55.9 56.7 Metformin + Sulfonylurea
Schernthaner 2015 720 52 61.8 72.6 Metformin
Seck 2010 1172 104 59.2 56.7 Metformin
Sheu 2015 1261 52 52.2 60.0 Insulin
Wainstein 2012 521 32 53.6 52.3 Diet + Exercise
EXAMINE 2013 5380 208 67.9 60.9 OADs
Weistock 2015 1098 26 47.4 54 Metformin
Williams-Herman 2012 306 24 52.0 53.7 Diet + Exercise
Table 1. Characteristics of the included trials. OADs, oral antidiabetics; NR, not reported.
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On the other hand, GLP-1 agonist use is not associated with an elevated risk of acute pancreatitis, as recently 
revealed by a meta-analysis from Storgaard et al.21. Receptors for GLP-1 are largely found in the pancreatic ducts 
and the pancreatic islets. Acinar and duct cells respond to GLP-1 therapy with proliferation22,23. A previous study 
in rats exposed to sitagliptin reported haemorrhagic pancreatitis in one rat and acinar-to-ductal metaplasia in 
others24. Therefore, the association between incretins and acute pancreatitis is biologically plausible. However, it 
remains unclear why DPP-4 inhibitors are associated with pancreatitis and GLP-1 agonists are not21.
Regarding pancreatic cancer, no association between use of gliptins and pancreatic cancer was observed, and 
TSA meta-analysis showed that there were enough patients randomised for this observation.
The main limitation of our meta-analysis was the duration of the trials (mean of 63.5, minimum and maxi-
mum of 24 and 260 weeks), which may be insufficient to evaluate the development of pancreatic cancer. We tried 
to overcome this limitation by including study duration as a covariate in the meta-regression, and this variable 
did not have an influence on the outcome. However, we must consider that this analysis might have low power 
owing to the number of included trials. Another limitation is the criteria used for diagnosis of acute pancreatitis 
in trials. In adjudicated trails, the diagnosis was confirmed by an adjudication committee and the criteria used 
were clearly described. However, in non-adjudicated trials, the criteria used are less straightforward. Nonetheless, 
restricting the analysis to adjudicated studies did not change the results. Furthermore, owing to the design of the 
present study, we were not able to explore whether there is a specific subgroup of diabetic patients with increased 
susceptibility to acute pancreatitis. The included trials did not describe the risk factors for this complication, such 
as hypertriglyceridaemia, alcohol consumption, and previous history of cholelithiasis. The only factor classically 
associated with acute pancreatitis that was mentioned was smoking status, which was similar in the intervention 
and control groups.
Finally, there is enough information to suggest a lack of association between the use of DPP-4 inhibitors and 
pancreatic cancer, but not acute pancreatitis. The latter seems to be a continued concern, and additional study 
data are needed. Despite this uncertainty, the apparent risk is small.
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